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Colchicine-induced leukopenia usually occurrs in intentional
or accidental overdoses or inappropriate use in combination
with intravenous and oral colchine; however, there have been
several reports of hematologic toxicity in short-term and
small-dose colchicine medication courses. We present two
cases of leukopenia induced by colchicine use concurrent
with immunosuppressants in Behçet's disease. We postulate
that the mechanism of colchicine-induced leukopenia might be
the destruction of circulating leukocytes and an inhibition of
leukocyte production by the immediate and direct toxic effect
of colchicine on idiosyncrasies unique to each patient. The
concurrently administered immunosuppressant might decrease
the threshold for hematologic toxicity of colchicine in the
leukocytes and their precursor cells.
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Sir, Behçet's disease (BD) is recurrent and long
standing inflammatory disease which is hard to
control in some patients. Colchicine appears to be
a promising and safe drug for BD with infrequent
or minor side effects.1 Common side effects of
colchicine including diarrhea and gastrointestinal
upset are mild and self-limited, however, severe
reactions like leukopenia, aplasticanemia, confu-
sion, azoospermia, alopecia, myopathy and
chorea-like syndrome may occur.2 We present two
cases of acute leukopenia after short-term use of
colchicine in BD patients who were concurrently
taking immunosuppresants.
A 58-year-old Korean woman (case 1) who had
been taking prednisolone and azathioprine for
two years and a 71-year-old Korean woman (case
2) who had been taking methotrexate for three
years. Both of them were diagnosed as incomplete
type BD according to RCJ Criteria.3 Oral colchicine
(1.2 mg per day) was added to alleviate mucocu-
taneous symptoms, and leukopenia was discovered
after adding oral colchicine, on 14th days in the
first patient and 3rd days in the second patient.
However, blood cell counts of both patients were
recovered after cessation of colchine and
immunosuppresants with conservative treatment
with G-CSF (Table 1). In case 2, neither colchicine
nor immunosuppresant administered afterward
and her symptoms are well controlled only with
sulfasalazine, aceclofenac and topical dexaltin
currently. On the other hand, in case 1,
prednisolone, analgesics and azathioprine were
restarted 5 months later due to intractable BD,
and regular laboratory studies showed no
abnormalities. Uveitis and aphthous ulcer of the
patient were not well controlled at that time, so
oral colchicine (1.2 mg per day) was added to her
regimen again. Ten days after adding colchicine,
the patient was readmitted due to septicshock
and leukopenia and she was died despite intensive
care.
It is assumed that colchicines was closely related
in leukopenia of both patients even though the
dose was small and the duration of colchicine use
was short. Our patients had received immuno-
suppressant drugs for a few years without
complications before taking colchicine, and the
prompt discontinuation of colchicine resulted in
recovery of the leukocyte count in both patients. In
addition, the leukopenicevent was repeated after
the re-initiation of colchicine therapy in case 1.
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It is hard to conclude that leucopenia was caused
by inhibiting microtubule assembly in mitosis by
colchicine because the dose of colchicine was too
small and leukopenia developed very rapidly after
Table 1. Blood Cell Count in the Patient of Case 1 (A) and Case 2 (B)
(A)
Date Day* WBC (/mm3) Hb/hct (g/dL, %) Platelet (× 1000/mm3)
2004. 09. 30 9130 12.8 (38.2) 215
2004. 11. 16 Day 0 Colchicine started
2004. 11. 23 Day 7 3190 12.2 (36.7) 124
2004. 11. 30 Day 14 1000 11.2 (33.7) 46
Colchicine, azathioprine quitted
2004. 12. 07 Day 22 500 9.2 (25.1) 110
2004. 12. 20 Day 35 4540 9.1 (25.1) 362
2005. 02. 22 2940 12.2 (36.5) 138
2005. 04. 04 5340 12.8 (40.0) 203
2005. 04. 12 Azathioprine restarted
2005. 05. 10 4350 12.8 (38.9) 208
2005. 06. 05 Day 0 Colchicine restarted
2005. 06. 15 Day 10 910 10.0 (29.2) 43
2005. 06. 29 Day 24 550 9.3 (28.2) 23
*the Day from Colchicine Started.
(B)
Date Day* WBC (/mm3) Hb/hct (g/dL, %) Platelet (x1000/mm3)
2005. 08. 23 Colchicine started
2005. 08. 25 Day 2 1220 8.6 (26.5) 43
Colchicine, methotrexate quitted
2005. 08. 27 Day 4 380 6.8 (19.5) 13
2005. 09. 10 Day 18 5870 9.8 (28.6) 373
Table 2. Blood Cell Count in the Patient of Case 2
Date Day* WBC (/mm3) Hb/hct (g/dL, %) Platelet (× 1000/mm3)
2005 .08. 23 Colchicine started
2005. 08. 25 Day 2 1220 8.6 (26.5) 43
Colchicine, methotrexate quitted
2005. 08. 27 Day 4 380 6.8 (19.5) 13
2005. 09. 10 Day 18 5870 9.8 (28.6) 373
*the day from Colchicine started.
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the administration.2 Bone marrow cellularities and
leukocyte counts were decreased and leukocytes
with abnormal morphology appeared in peripheral
blood in both of our patients. So the immediate
destruction of leukocytes with an accompanying
inhibition of leukocyte production might have
been caused by the direct toxiceffect of colchicines
and it could be the mechanism of colchicine-
induced acute leukopenia superimposed on idio-
syncrasies. Proposed mechanisms of acute
colchicine-induced leukopenia were decreased
clearance of the drug in the patients with
underlying hepatic or renal dysfunction, drug
interaction of colchicine with some drugs which
inhibit P-glycoprotein, and concurrent viral
infection.4,5 However, our patients did not have any
evidence of hepaticdysfunction, renal dysfunction
or usage of drugs which inhibit P-glycoprotein.
And serologictests for cytomegalovirus, rubella
virus, measles virus, Ebstein-Barr virus, human
immunodeficiency virus and varicella zoster virus
were negative. We propose that immunosuppre-
sants might decrease the threshold for the
idiosyncraticreaction of colchicine in leukocytes
and precursor cells. In fact, it is well known that
those cells which are chronically exposed to
immunosuppressant are vulnerable to the toxicity
of other drugs and infections, and also the
concentration of colchicine and immunosuppresants
of the leukocytes and precursor cells are higher
than the concentration of serum due to much
slower clearance of the compound.6,7
We share our case to highlight colchicines use in
the patients taking immunosuppressant can induce
acute leukopenia which is acute, unpredictable and
may be irreversible and life-threatening. We propose
that any patient who is treated with colchicine may
be at risk of hematologictoxicity and should be
monitored frequently, especially in case of
concurrently using immunosuppressants as well as
other drugs known to have interactions with
colchicine. In addition, prompt administration of
G-CSF must be considered in the patient with
colchicine-induced leukopenia, because the admi-
nistration of G-CSF is known to be very useful and
effective treatment regardless of whether colchicine-
induced leukopenia is caused by overdose or
long-term treatment or an idiosyncraticreaction.8,9
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